Sinocare Inc (SHE: 300298), a Chinese medical device company, has announced that it has received market approval from the US Food and Drug Administration (FDA) for its TRUNESS/ TRUNESS AIR blood glucose monitoring system product. The TRUNESS blood glucose monitoring system includes the TRUNESS blood glucose meter and corresponding test strips, and the TRUNESS AIR system comprises the TRUNESS AIR blood glucose meter and test strips. These products are designed for quantitative measurement of glucose levels in capillary whole blood and are intended for use by diabetes patients at home to monitor the effectiveness of their diabetes management plans. The systems are single-use and intended for in vitro diagnostic purposes, not for the diagnosis or screening of diabetes, and are not suitable for use in newborns.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
